Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY306 in Relapsed or Refractory CD70+ Hematologic Tumors
NCT06837389Phase 1Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2025
- Primary completion
- Mar 2026
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of JY306 in hematologic neoplasms, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Incidence and severity of adverse events and adverse reactions at 1 year. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
JY306
03
Conditions
hematologic neoplasms
Beyond the preview
Go deeper on NCT06837389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837389.